{
    "clinical_study": {
        "@rank": "75658", 
        "acronym": "XB", 
        "arm_group": [
            {
                "arm_group_label": "Xuebi formula", 
                "arm_group_type": "Experimental", 
                "description": "Xuebi formula , one dosage ,every day, treat 6 months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "A Randomized, Parallel-controlled, Clinical Study to Evaluate the Efficacy of Xuebi\n      Prescription Compared With Placebo in the Treatment of Diabetic Peripheral Neuropathy(Qi\n      Deficiency and Blood Stasis)"
        }, 
        "brief_title": "A Study of Xuebi Formula for Diabetic Peripheral Neuropathy(Qi-deficiency and Blood-stasis)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetic Peripheral Neuropathy", 
            "Diabetes", 
            "Chinese Herbs"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Nervous System Diseases", 
                "Demyelinating Diseases", 
                "Polyneuropathies", 
                "Nerve Compression Syndromes", 
                "Neurologic Manifestations", 
                "Neurotoxicity Syndromes", 
                "Diabetic Neuropathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Charged by the sponsor in line with traditional Chinese medicine Qi deficiency and blood\n      stasis syndrome 60 cases have DPN\uff0cthey were randomly divided into Chinese herbal compound\n      Xuebi prescription group and placebo group. The treatment groups were compared 24-week\n      composite score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  according to the 1999 WHO criteria, in accordance with the diagnostic criteria for\n             type 2 diabetes.\n\n          -  according to the diagnostic standard of diabetes peripheral nerve lesions.\n\n          -  age range 30-70 years.\n\n          -  Syndrome  of traditional Chinese medicine is Qi deficiency and blood stasis.\n\n          -  FBG < 13.9mmol/L, HbA1c<10%.\n\n          -  signed the informed consent\n\n        Exclusion Criteria:\n\n          -  did not meet the inclusion criteria, or incomplete information affect the clinical\n             syndrome differentiation type;\n\n          -  repeated hypoglycemia reaction, nearly a month diabetic ketoacidosis, DKAand severe\n             infections;\n\n          -  blood pressure without control or after control, SBP \u2265 160mmHg or (and)DBP \u2265 100mmHg;\n\n          -  TG\u2265 5.6mmol / L;\n\n          -  diabetic lower extremity vascular disease (resting ankle brachial index in patients\n             with ABI \u2264 0.90 or lower extremity ultrasound vascular stenosis > 50%).\n\n          -  pregnancy, to pregnant or lactating women;\n\n          -  the ingredients allergy of Chinese herbal medicine and allergic constitution person;\n\n          -  psychiatric patients;\n\n          -  have serious heart, lung, liver, kidney, brain and other complications overassociated\n             with other severe primary diseases;\n\n          -  other patients had participated in clinical trials or are in other clinical trials\n             before the test in January;\n\n          -  in the past 5 years with alcohol and / or psychoactive substances, drug abuse and\n             dependence;\n\n          -  according to the researcher's judgment, can reduce the possibility of the group or\n             other diseases or conditions were complicated, such as work environment change\n             frequently, the living environment is not stable, easy to cause lost\n\n          -  hepatic, renal impairment (ALT, AST is greater than 2.5 times the upper limit of\n             normal value; serum creatinine greater than 1.5 times the upper limit of normal\n             value);\n\n          -  demyelinating lesions or from other causes of polyneuropathy patients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039544", 
            "org_study_id": "20131205"
        }, 
        "intervention": [
            {
                "arm_group_label": "Xuebi formula", 
                "intervention_name": "Xuebi formula", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Parallel-controlled, Clinical Study to Evaluate the Efficacy of Xuebi Prescription Compared With Placebo in the Treatment of Diabetic Peripheral Neuropathy(Qi Deficiency and Blood Stasis)", 
        "other_outcome": {
            "description": "Adverse events with records at any time.", 
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "24Weeks"
        }, 
        "overall_contact": {
            "email": "15101016416@126.com", 
            "last_name": "qiang zhou, PHD", 
            "phone": "15101016416", 
            "phone_ext": "0086"
        }, 
        "overall_official": {
            "affiliation": "Guang'anmen Hospital", 
            "last_name": "Xiaolin Tong, PHD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Scores of TCM clinical symptom. Using statistical table score, main symptoms and secondary symptoms according to the degree is divided into light, medium, heavy, the main symptoms were recorded 2, 4, 6 points, the secondary symptoms were recorded 1, 2, 3 points. No symptomatic record 0 points. Before the study, of 4, 8, 12, 16, 20, 24 week each recorded 1 times. Description of tongue and pulse only, not scoring.\nthe clinical scoring system of Toronto (TCSS). TCSS includes a score of neural symptoms, nerve reflex scores and sensory examination , a total of 19 points.Before the study, of 4, 8, 12, 16, 20, 24 week each scoring 1 times.According to the classification standard, 0-5 points does not have DPN, 6-8 points for mild DPN,  9-11 points for moderate DPN, 12-19 points for severe DPN.", 
            "measure": "Change in Scores of TCM clinical symptom and the clinical scoring system of Toronto (TCSS)", 
            "safety_issue": "No", 
            "time_frame": "24weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039544"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guang'anmen Hospital of China Academy of Chinese Medical Sciences", 
            "investigator_full_name": "Fengmei Lian", 
            "investigator_title": "chair", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Nerve conduction velocity are recorded at 0,12th,24th weeks.", 
            "measure": "Change in Nerve conduction velocity", 
            "safety_issue": "No", 
            "time_frame": "24Weeks"
        }, 
        "source": "Guang'anmen Hospital of China Academy of Chinese Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guang'anmen Hospital of China Academy of Chinese Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}